Department of Drug Metabolism and Pharmacokinetics, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
Drug Metab Dispos. 2011 Mar;39(3):373-82. doi: 10.1124/dmd.110.035147. Epub 2010 Dec 8.
Reaction phenotyping using recombinant human cytochromes P450 (P450) has great utility in early discovery. However, to fully realize the advantages of using recombinant expressed P450s, the extrapolation of data from recombinant systems to human liver microsomes (HLM) is required. In this study, intersystem extrapolation factors (ISEFs) were established for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 using 11 probe substrates, based on substrate depletion and/or metabolite formation kinetics. The ISEF values for CYP2C9, CYP2D6, and CYP3A4 determined using multiple substrates were similar across substrates. When enzyme kinetics of metabolite formation for CYP1A2, 2C9, 2D6, and 3A4 were used, the ISEFs determined were generally within 2-fold of that determined on the basis of substrate depletion. Validation of ISEFs was conducted using 10 marketed drugs by comparing the extrapolated data with published data. The major isoforms responsible for the metabolism were identified, and the contribution of the predominant P450s was similar to that of previously reported data. In addition, phenotyping data from internal compounds, extrapolated using the rhP450-ISEF method, were comparable to those obtained using an HLM-based inhibition assay approach. Moreover, the intrinsic clearance (CL(int)) calculated from extrapolated rhP450 data correlated well with measured HLM CL(int). The ISEF method established in our laboratory provides a convenient tool in early reaction phenotyping for situations in which the HLM-based inhibition approach is limited by low turnover and/or unavailable metabolite formation. Furthermore, this method allows for quantitative extrapolation of HLM intrinsic clearance from rhP450 phenotyping data simultaneously to obtaining the participating metabolizing enzymes.
使用重组人细胞色素 P450(P450)进行反应表型分析在早期发现中具有很大的作用。然而,为了充分利用使用重组表达 P450 的优势,需要将数据从重组系统外推到人肝微粒体(HLM)。在这项研究中,使用 11 种探针底物,基于底物耗竭和/或代谢物形成动力学,建立了 CYP1A2、CYP2C8、CYP2C9、CYP2C19、CYP2D6 和 CYP3A4 的系统间外推因子(ISEF)。使用多种底物确定的 CYP2C9、CYP2D6 和 CYP3A4 的 ISEF 值在底物之间相似。当使用代谢物形成的酶动力学对 CYP1A2、2C9、2D6 和 3A4 进行研究时,基于底物耗竭确定的 ISEF 值通常在 2 倍以内。通过使用 10 种市售药物对 ISEF 进行验证,将外推数据与已发表的数据进行比较。确定了负责代谢的主要同工酶,并确定了主要 P450 的贡献与先前报道的数据相似。此外,使用 rhP450-ISEF 方法外推的内部化合物表型数据与使用 HLM 基于抑制测定方法获得的数据相当。此外,从外推的 rhP450 数据计算出的内在清除率(CL(int))与测量的 HLM CL(int) 相关性良好。我们实验室建立的 ISEF 方法为 HLM 基于抑制的方法因低周转率和/或无法形成代谢物而受到限制的情况下的早期反应表型分析提供了一种方便的工具。此外,该方法允许从 rhP450 表型数据定量外推 HLM 内在清除率,同时获得参与代谢的酶。